Neuronetics to Report First Quarter 2026 Financial and Operating Results and Host Conference Call
Rhea-AI Summary
Neuronetics (NASDAQ: STIM) will release first quarter 2026 financial and operating results before market open on Tuesday, May 5, 2026.
The company will host a conference call at 8:30 a.m. Eastern Time the same day, with a live listen-only webcast and telephone registration available for participants.
Positive
- None.
Negative
- None.
News Market Reaction – STIM
In the Apr 21 session, STIM declined 5.06%, reflecting a notable negative market reaction. Argus tracked a trough of -13.3% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Conferences,earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 03 | Earnings call date | Neutral | -1.6% | Set date and time for Q4 2025 results and conference call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior earnings-date announcement on Mar 3, 2026 saw a modest -1.55% move, suggesting limited typical reaction to scheduling releases.
Over recent months, Neuronetics has reported strong growth with Q4 2025 revenue of $41.8M and $149.2M for full-year 2025, alongside a $39.1M net loss and reaffirmed 2026 guidance. Activist activity emerged in early April 2026 as a 14.12% holder pushed for strategic alternatives, coinciding with leadership transitions and cost reductions. Against this backdrop, the current announcement simply schedules the Q1 2026 earnings release and call, following a similar Q4 2025 earnings-date notice on Mar 3, 2026 that saw only a mild price move.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MALVERN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced that it plans to release first quarter 2026 financial and operating results prior to market open on Tuesday, May 5, 2026. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.
The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/3pztkve5. To listen to the conference call on your telephone, participants may register for the call here. While it is not required, it is recommended you join 10 minutes prior to the event start.
About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. (“Greenbrook”) treatment centers across the United States, offering NeuroStar Advanced Therapy for the treatment of major depressive disorder (“MDD”) and other mental health disorders. NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (“TMS”) treatment for MDD in adults, and is backed by the largest clinical data set of any TMS treatment system for depression, including the world’s largest depression outcomes registry. Greenbrook treatment centers also offer SPRAVATO® (esketamine) nasal spray, a prescription medicine indicated for the treatment of treatment-resistant depression in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior in conjunction with an oral antidepressant.1
The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com.
Investor Contact:
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
ir@neuronetics.com
Media Contact:
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com
References
1 The effectiveness of SPRAVATO® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO®. For more important safety information about SPRAVATO®, please visit spravatohcp.com.
